Avid Bioservices has appointed Kerri McCullough Wood as Chief Commercial Officer (CCO).

Wood is a seasoned biopharma executive with nearly 30 years of experience across Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organisation (CDMO), and drug product services. She joins Avid following her role as Chief Commercial Officer (CCO) at TAPI, a division of Teva, where she led a global organisation spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong partnerships with global pharmaceutical companies, and enhancing organisational performance across the business.

In her role, McCullough Wood will lead Avid's global commercial organisation, including business development, marketing, and strategic partnerships. She will focus on accelerating pipeline growth, strengthening client relationships, and further aligning the company's commercial strategy with its expanding capabilities across early-phase development through commercial manufacturing.

Kenneth Bilenberg, Group President and Chief Executive Officer (CEO), Avid Bioservices, said, "Kerri joins Avid at an important time for the company. We've made significant investments in our early-phase Center of Excellence and expanded our manufacturing capabilities to meet growing demand for US-based biologics development and manufacturing. Kerri brings a strong track record of partnership, operational excellence, and program execution that will help us continue delivering for the clients and patients we serve."

Wood's appointment comes as Avid continues to scale its operations to support biopharma companies across the full development lifecycle, from early-phase programs through commercial manufacturing.

The company's focus on speed, quality, and operational predictability, combined with its US-based manufacturing footprint, positions it to meet increasing industry demand for reliable and responsive CDMO partners.

Wood said, "I'm excited to join Avid at such a pivotal point in its growth. The company has built a strong reputation for quality, flexibility, and partnership. I look forward to working with the team to expand our commercial reach, deepen client relationships, and help bring more therapies to patients."

With Wood's leadership, Avid will continue advancing its mission to set the standard for quality and partnership in biologics manufacturing, enabling the delivery of therapies that transform patient lives.